

Dr. Agarwal's Health Care

Estimate change	↑
TP change	↔
Rating change	↔

Bloomberg	AGARWALE IN
Equity Shares (m)	317
M.Cap.(INRb)/(USDb)	156.5 / 1.6
52-Week Range (INR)	568 / 401
1, 6, 12 Rel. Per (%)	2/14/9
12M Avg Val (INR M)	105

Financials & Valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	20.8	25.6	31.3
EBITDA	5.7	7.1	8.7
Adjusted PAT	1.3	1.8	2.6
EBIT Margin (%)	14.1	15.0	16.3
Cons. Adj EPS (INR)	4.2	5.8	8.4
EPS Growth (%)	59.0	37.5	45.2
BV/Share (INR)	64.7	70.5	78.9

Ratios

Net D-E	-0.1	-0.2	-0.2
RoE (%)	6.8	8.6	11.3
RoCE (%)	8.9	10.6	12.9
Payout (%)	0.0	0.0	1.0

Valuations

P/E (x)	117.0	85.0	58.6
EV/EBITDA (x)	27.2	21.8	17.5
Div. Yield (%)	0.0	0.0	0.0
FCF Yield (%)	-6.4	4.4	2.9
EV/Sales (x)	7.5	6.0	4.9

Shareholding Pattern (%)

As On	Jun-26	Mar-26	Jun-25
Promoter	32.3	32.4	32.4
DII	27.8	27.9	26.6
FII	37.9	37.9	39.2
Others	2.0	1.9	1.9

FII includes depository receipts

CMP: INR494 **TP: INR620 (+26%)** **Buy**

Healthy start; growth broadens across the network

Strong SSSG and rapid network expansion

- Dr. Agarwal Healthcare (DAHL) delivered better-than-expected financial performance with a 4%/8% beat on revenue/EBITDA. The PAT beat was much higher (23%) due to further support from lower tax rate.
- There was robust YoY growth across centers, both mature (3+ years into operations) and emerging facilities. DAHL reported 16.3% same store sales growth (SSSG) for all facilities set-up/acquired up to FY23. Facilities that commenced operations in FY24/FY25 witnessed 19.6%/38.6% YoY revenue growth in 1QFY27.
- Growth was backed by sustained momentum in the number of surgeries performed, supported by healthy improvement in realization.
- Region-wise, the newer North region continued to witness strong YoY growth in surgeries (+37% YoY), while South, West, and East India recorded ~13% YoY growth.
- We raise our estimates by 5%/2% for FY27/FY28, factoring in: a) an increased share of higher-end surgeries, and b) faster addition of new facilities.
- We value DAHL at 25x EV/EBITDA for the surgery business, 15x EV/EBITDA for the opticals business, and 10x EV/EBITDA for the pharmacy business, adjusted for its stake in Dr. Agarwal Eye Hospital/Thind hospital), and arrive at a TP of INR620.

Operational leverage supports earnings growth

- DAHL's 1QFY27 revenue grew 26% YoY to INR6.1b (our estimate: INR5.9b).
- EBITDA margin expanded 160bp YoY to 27.8% (our estimate: 26.7%).
- Consequently, EBITDA grew 33.3% YoY to INR1.7b (our estimate: INR1.6b).
- PAT came in at INR452m in 1QFY27, up 50.5% YoY from INR301m in 1QFY26.

Surgical business continues to anchor growth

- Surgeries grew 26.7% YoY to INR4b (66% of overall revenue).
- Diagnosis, Consultations, and Others grew 14.5% YoY to INR737m (12% of overall revenue).
- Opticals, Contact Lens, and Accessories grew 32.8% YoY to INR835m (14% of overall revenue).
- Eye Care Related Pharma Products grew 27.5% YoY to INR522m (8% of overall revenue).
- The company added 18 new facilities in 1QFY27, expanding its network to 304 facilities.
- Number of Surgeries increased 15.5% YoY to 91,082 in 1QFY27, while Average Revenue per Surgery increased 9.8% YoY to INR44,426.

Highlights from the management commentary

- The 16% SSSG was equally driven by volume and value growth. Premiumization was the primary driver of higher realizations, while volume growth was driven by higher patient footfalls/OPD (6%) and by conversion to surgeries (2%).
- 18 new facilities included 1 tertiary facility in Thane and 15 secondary facilities (four in Maharashtra, two each in TN, Delhi, and Kerala, one each in Punjab, Rajasthan, Telangana, Andhra Pradesh, and Uttar Pradesh). DAHL launched primary facilities in J&K and Tamil Nadu.
- High-end surgeries formed 29% of total cataract surgeries for the quarter.
- The merger with Dr. Agarwal Eye Hospital is expected to be completed by mid-November.
- Leadership changes in Gujarat led to considerable revenue growth in Gujarat.
- There has been a strong recovery in revenue from the Punjab/Haryana facilities, which were impacted by floods in the previous year.

Quarterly performance

Y/E March	FY26				FY27E				FY26	FY27E	FY27	
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1QE	vs Est
Net Sales	4,874	4,987	5,299	5,641	6,140	6,129	6,516	6,841	20,801	25,626	5,923	3.7%
YoY Change (%)	20.8	19.7	23.0	22.6	26.0	22.9	23.0	21.3	21.6	23.2	21.5	
Total Expenditure	3,596	3,626	3,858	4,026	4,436	4,468	4,731	4,939	15,105	18,574	4,341	
EBITDA	1,279	1,361	1,441	1,615	1,704	1,661	1,785	1,902	5,696	7,052	1,581	7.8%
YoY Change (%)	23.3	27.3	31.5	21.4	33.3	22.0	23.9	17.8	25.7	23.8	23.7	
Margins (%)	26.2	27.3	27.2	28.6	27.8	27.1	27.4	27.8	27.4	27.5	26.7	
Depreciation	630	679	688	767	783	766	815	855	2,762	3,219	744	
EBIT	649	683	754	848	921	895	971	1,047	2,933	3,833	837	
YoY Change (%)	34.7	37.2	46.6	16.8	41.9	31.0	28.8	23.4	32.1	30.7	29.0	
Margins (%)	13.3	13.7	14.2	15.0	15.0	14.6	14.9	15.3	14.1	15.0	14.1	
Interest	247	226	211	221	234	254	247	241	905	976	254	
Other Income	134	79	105	126	64	69	70	68	444	271	127	
PBT before EO expense	536	537	648	753	751	710	795	873	2,473	3,129	710	
Extra-Ord expense	0	0	0	-13	0	0	0	0	13	0	0	
PBT	536	537	648	766	751	710	795	873	2,486	3,129	710	
Tax	155	172	211	267	201	213	242	253	805	910	241	
Rate (%)	29.0	32.0	32.6	34.8	26.8	30.0	30.5	29.0	32.4	29.1	34.0	
MI & P/L of Asso. Cos.	80	68	99	103	98	100	100	100	350	399	100	
Reported PAT	301	297	337	397	452	396	452	519	1,332	1,820	368	
Adj PAT	301	297	337	388	452	396	452	519	1,323	1,820	368	22.8%
YoY Change (%)	148.3	79.5	80.3	8.4	50.5	33.5	33.9	33.7	59.0	37.5	22.5	
Margins (%)	6.2	6.0	6.4	6.9	7.4	6.5	6.9	7.6	6.4	7.1	6.2	
EPS	1.0	0.9	1.1	1.2	1.4	1.3	1.4	1.7	4.2		1.2	22.9%

E: MOFSL Estimates



Conference call highlights

- DAHL remains on track to add 42 facilities during the remainder of FY27, with around 30 LOIs already signed.
- Management indicated healthy visibility on doctor additions for upcoming facilities, with recruitment and agreements already underway.
- DAHL expects volume growth to remain healthy in the near term, while value growth is likely to be driven by premiumization, adoption of newer technologies (including SINTA cataract), and increasing insurance penetration.
- Management expects gross margins to expand over time, supported by a richer procedure mix and higher adoption of advanced technologies.
- Facilities acquired up to FY23 (116 facilities) generated revenue of INR4.6b in 1QFY27, registering 16.3% YoY growth.
- The payor mix comprised 68% cash and 28% insurance, with the remaining coming from government schemes.

Operational momentum supported by robust network expansion

- Revenue from operations grew 26.0% YoY to INR6.1b in 1QFY27, supported by healthy growth across surgeries, diagnostics, consultations, opticals, and eye care-related pharma products.
- Surgical services remained the largest revenue contributor, accounting for 65.9% of revenue (vs. 65.6% in 1QFY26), while diagnostics, consultations and other services contributed 13.6%, opticals 12.0%, and eye care-related pharma products 8.5%.
- The company served a record 882k patients during the quarter, up 25.1% YoY, while the number of surgeries performed increased 15.5% YoY to 91.1k, reflecting sustained demand and improving utilization across the network.
- Cataract surgeries grew 16.5% YoY to 67.4k, refractive surgeries increased 8.8% YoY to 4.0k, while other surgeries rose 13.3% YoY to 19.6k, indicating broad-based procedural growth.
- Average revenue per surgery increased to ~INR44.4k in 1QFY27 (vs. ~INR40.5k in 1QFY26), implying a continued improvement in the case mix, realizations, and contribution from premium procedures.
- The company expanded its medical team to 1,057 doctors, up from 857 a year ago, supporting capacity expansion and higher patient throughput.
- Geographic performance remained broad-based, with South India growing 22.8% YoY to INR3.9b, West rising 24.3% YoY to INR0.9b, North delivering the strongest growth of 50.4% YoY to INR0.6b, and East increasing 20.8% YoY to INR0.2b.
- Mature facilities continued to anchor performance, contributing 79.0% of revenue in 1QFY27, while emerging facilities contributed 21.0%, providing a meaningful runway for future revenue scaling as recently added centers mature.
- Same-store sales growth remained healthy at 16.3% for facilities established or acquired up to FY23, reflecting sustained demand and improving operating performance across the mature network.
- We expect DAHL to deliver ~2% revenue CAGR over FY26-28, driven by continued network expansion, healthy same-store sales growth, increasing utilization of emerging facilities, higher surgical throughput, improving revenue per surgery, and a rising contribution from mature centers.

Aggressive expansion to support long-term growth

- The company expanded its network to 304 facilities (285 in India and 19 international) as of Jun'26, compared with 249 facilities a year ago, while the number of surgical centers increased to 146 from 116.
- During 1QFY27, the company added a record 16 surgical facilities (highest-ever quarterly addition), comprising 1 tertiary and 15 secondary centers, while also adding 2 primary facilities. Two primary facilities were closed during the quarter, resulting in a net addition of 16 facilities.
- Since FY23, the company has added 166 greenfield facilities, demonstrating strong execution of its organic expansion strategy across key markets.
- Management plans to add 60 new facilities during FY27, including 40 surgical centers and 20 primary centers, with 42 facilities expected to be launched over the remaining FY27 period after commissioning 18 facilities in 1QFY27.


- The planned expansion remains well diversified across regions, with 24 facilities in the South, 15 in the West, 16 in the North, and 5 in the East, strengthening the company's presence across high-growth ophthalmology markets.
- The continued addition of surgical centers, improving contribution from emerging facilities, and healthy same-store growth across mature centers provide a strong foundation for sustained revenue growth and higher asset utilization over the medium term.

Reiterate BUY

- We raise our estimates by 5%/2% for FY27/FY28, factoring in: a) an increased share of higher-end surgeries, and b) faster addition of new facilities.
- We value DAHL at 25x EV/EBITDA for the surgery business, 15x EV/EBITDA for the opticals business, and 10x EV/EBITDA for the pharmacy business, adjusted for its stake in Dr. Agarwal Eye Hospital/Thind hospital, and arrive at a TP of INR620.


Story in charts

Exhibit 1: Expect a revenue CAGR of 23% over FY26-28




Source: MOFSL, Company

Exhibit 2: EBITDA margin to expand 50bp over FY26-28




Source: MOFSL, Company

Exhibit 3: 18 facilities added in 1QFY27




Source: MOFSL, Company

Exhibit 4: 100% facilities added on an organic basis in 1QFY27




Source: MOFSL, Company

Exhibit 5: Regional presence



Source: MOFSL, Company

Exhibit 6: PAT to post a 41% CAGR over FY26-28



Source: MOFSL, Company

Financials and valuations

Consolidated - Income Statement

(INRm)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	6,961	10,180	13,322	17,110	20,801	25,626	31,286
Change (%)	NA	46.2	30.9	28.4	21.6	23.2	22.1
Raw Materials	1,600	2,339	3,010	3,886	4,570	5,437	6,600
Consultancy charges	2,326	3,375	4,467	5,789	6,987	8,537	10,451
Other Expenses	1,214	1,762	2,222	2,904	3,548	4,601	5,509
Total Expenditure	5,140	7,476	9,699	12,578	15,105	18,574	22,560
% of Sales	73.8	73.4	72.8	73.5	72.6	72.5	72.1
EBITDA	1,821	2,703	3,623	4,532	5,696	7,052	8,726
Margin (%)	26.2	26.6	27.2	26.5	27.4	27.5	27.9
Depreciation	977	1,283	1,704	2,313	2,762	3,219	3,618
EBIT	845	1,420	1,919	2,220	2,933	3,833	5,108
Int. and Finance Charges	454	720	956	1,088	905	976	953
Other Income	177	135	443	460	444	271	563
PBT bef. EO Exp.	568	836	1,406	1,592	2,473	3,129	4,718
EO Items	0	0	0	7	13	0	0
PBT after EO Exp.	568	836	1,406	1,599	2,486	3,129	4,718
Total Tax	136	-196	455	495	805	910	1,614
Tax Rate (%)	24.0	-23.5	32.4	31.0	32.4	29.1	34.2
Minority Interest	55	91	120	269	350	399	462
Reported PAT	377	941	831	835	1,332	1,820	2,642
Adjusted PAT	377	941	831	832	1,323	1,820	2,642
Change (%)	NA	149.6	-11.7	0.2	59.0	37.5	45.2
Margin (%)	5.4	9.2	6.2	4.9	6.4	7.1	8.4

Consolidated - Balance Sheet

(INRm)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	69	79	94	316	317	317	317
Total Reserves	2,055	6,216	13,300	18,350	19,938	21,757	24,400
Net Worth	2,124	6,296	13,394	18,666	20,255	22,074	24,716
Minority Interest	214	295	401	602	942	1,342	1,804
Total Loans	2,902	3,562	3,878	2,469	1,573	1,573	1,573
Deferred Tax Liabilities	-129	-530	-352	-230	-263	-263	-263
Lease Liabilities	3,431	5,012	5,786	7,140	9,089	9,747	10,404
Deferred acquisition liabilities	80	902	1,227	4,343	3,846	5,620	2,420
Capital Employed	8,623	15,536	24,334	32,990	35,443	40,093	40,655
Gross Block	9,344	15,207	19,370	26,724	32,947	37,096	40,725
Less: Accum. Deprn.	3,810	5,009	6,527	8,840	11,602	13,579	15,680
Net Fixed Assets	5,534	10,198	12,843	17,884	21,345	23,517	25,045
Goodwill on Consolidation	1,481	2,732	4,619	7,348	7,358	7,358	7,358
Capital WIP	284	994	1,182	1,532	2,435	3,787	1,657
Total Investments	214	601	5,044	3,610	3,180	3,180	3,180
Curr. Assets, Loans&Adv.	2,606	3,173	3,473	6,042	4,830	7,434	9,669
Inventory	329	360	519	803	940	1,595	1,948
Account Receivables	567	763	968	1,236	1,609	1,982	2,420
Cash and Bank Balance	1,167	1,485	1,249	2,581	1,292	2,638	3,814
Loans and Advances	543	564	737	1,422	989	1,218	1,487
Curr. Liability & Prov.	1,497	2,161	2,827	3,426	3,706	5,183	6,255
Account Payables	891	1,013	1,330	1,531	1,493	2,532	3,092
Other Current Liabilities	524	1,018	1,326	1,680	1,885	2,322	2,835
Provisions	82	130	172	216	328	328	328
Net Current Assets	1,110	1,011	646	2,616	1,124	2,251	3,414
Appl. of Funds	8,623	15,536	24,334	32,990	35,443	40,093	40,655

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)							
EPS	1.2	3.0	2.7	2.7	4.2	5.8	8.4
Cash EPS	3.4	5.6	6.2	7.5	10.0	12.4	15.5
BV/Share	6.8	20.1	42.8	59.6	64.7	70.5	78.9
Valuation (x)							
P/E	410.6	164.5	186.3	186.0	117.0	85.0	58.6
Cash P/E	147.0	87.7	80.3	65.5	49.3	39.9	32.0
P/BV	72.9	24.6	11.6	8.3	7.6	7.0	6.3
EV/Sales	5.1	4.1	11.6	9.0	7.5	6.0	4.9
EV/EBITDA	19.6	15.3	42.6	34.1	27.2	21.8	17.5
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	2.2	-30.1	-5.5	-15.1	-6.4	4.4	2.9
Return Ratios (%)							
RoE	17.7	22.4	8.4	5.2	6.8	8.6	11.3
RoCE	15.2	24.2	10.9	8.4	8.9	10.6	12.9
RoIC	25.5	24.4	11.8	10.0	9.9	12.2	14.0
Working Capital Ratios							
Fixed Asset Turnover (x)	0.7	0.7	0.7	0.6	0.6	0.7	0.8
Asset Turnover (x)	0.8	0.7	0.5	0.5	0.6	0.6	0.8
Inventory (Days)	17	13	14	17	16	23	23
Debtor (Days)	30	27	27	26	28	28	28
Creditor (Days)	47	36	36	33	26	36	36
Leverage Ratio (x)							
Current Ratio	1.7	1.5	1.2	1.8	1.3	1.4	1.5
Interest Cover Ratio	1.9	2.0	2.0	2.0	3.2	3.9	5.4
Net Debt/Equity	0.7	0.2	-0.2	-0.2	-0.1	-0.2	-0.2

Consolidated - Cash Flow Statement

(INRm)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	568	836	1,406	1,592	2,473	3,129	4,718
Depreciation	977	1,283	1,704	1,483	1,754	1,977	2,101
Interest & Finance Charges	454	720	956	1,088	905	976	953
Direct Taxes Paid	-156	-354	-321	-495	-805	-910	-1,614
(Inc)/Dec in WC	-150	-125	46	-637	202	219	13
CF from Operations	1,692	2,360	3,791	3,031	4,528	5,391	6,172
Others	-49	-29	-331	-460	1,087	-271	-563
CF from Operating incl EO	1,643	2,331	3,460	2,571	5,615	5,119	5,608
(Inc)/Dec in FA	-1,495	-4,718	-5,147	-7,317	-7,633	-3,727	-4,700
Free Cash Flow	148	-2,387	-1,688	-4,746	-2,017	1,393	908
(Pur)/Sale of Investments	-73	-397	-4,038	1,434	430	0	0
Others	15	25	46	460	444	271	563
CF from Investments	-1,554	-5,091	-9,139	-5,422	-6,758	-3,455	-4,137
Issue of Shares	0	3,009	6,401	4,442	266	0	0
Inc/(Dec) in Debt	414	321	-516	-1,409	-896	0	0
Interest Paid	-208	-293	-322	-1,088	-905	-976	-953
Dividend Paid	0	-4	-8	0	0	0	0
Others	148	0	-29	1,372	1,967	658	658
CF from Fin. Activity	354	3,033	5,527	3,317	432	-318	-295
Inc/Dec of Cash	444	274	-152	465	-711	1,346	1,176
Opening Balance	552	1,167	1,485	1,249	2,581	1,292	2,638
Others	171	44	-84	868	-578	0	0
Closing Balance	1,167	1,485	1,249	2,581	1,292	2,638	3,814

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	$\geq 15\%$
SELL	$< -10\%$
NEUTRAL	$< -10\%$ to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.